- Home
- Companies
- Virpax Pharmaceuticals
- News
- Leucine-Enkephalin as a Novel ...
Leucine-Enkephalin as a Novel Analgesic: Efficacy and Safety in Pre-Clinical Models
Source: Virpax Pharmaceuticals
Endogenous peptides with analgesic potential include endorphins via the mu receptor, dynorphins via the kappa receptor and enkephalins via the delta receptor. Kappa and delta opioid agonists have been shown to provide analgesic benefit while sparing toxic mu agonist toxicity1 . Preclinical data supports analgesia from enkephalin without significant opioid tolerance, or drug liking. Unfortunately, exogenous enkephalins are rapidly degraded and have difficulty accessing the CNS2 Using a novel encapsulation method known as Molecular Envelope Technology (MET), leucine-enkephalin, or L-ENK can be delivered via an intranasal formulation of “protected” nanoparticles. MET increases dwell time in the nares promoting delivery via the olfactory route across the blood brain barrier and into the central nervous system.
-
Most popular related searches
Customer comments
No comments were found for Leucine-Enkephalin as a Novel Analgesic: Efficacy and Safety in Pre-Clinical Models. Be the first to comment!